60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reiterated by equities research analysts at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 28th.

60 Degrees Pharmaceuticals Trading Down 12.9 %

SXTP opened at $2.50 on Tuesday. The firm has a 50 day moving average of $2.19 and a two-hundred day moving average of $4.31. The firm has a market capitalization of $3.68 million, a PE ratio of -0.25 and a beta of 3.41. 60 Degrees Pharmaceuticals has a 12-month low of $1.41 and a 12-month high of $35.99.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.